Company:  EVOFEM BIOSCIENCES, INC. (EVFM)
Form Type:  424B5
Filing Date:  5/23/2022 
CIK:  0001618835 
Address:  12400 HIGH BLUFF DRIVE
SUITE 600
 
City, State, Zip:  SAN DIEGO, California 92130 
Telephone:  (858) 550-1900 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$0.17  
Change: 
0.002 (1.06%)  
Trade Time: 
03:58 PM EST  
Market Cap: 
$14.70M
Trade EVFM now with 

© 2022  
Description of Business
We are a San Diego-based commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). Our first commercial product, Phexxi, was approved by the FDA on May 22, 2020 and is the first and only FDA-approved, hormone-free, woman-controlled, on-demand prescription contraceptive gel for women. We commercially launched Phexxi in September 2020 in the United States. We intend to commercialize Phexxi in all other global markets through partnerships or licensing agreements. We are evaluating Phexxi for two potential new indications: the prevention of chlamydia and the prevention of gonorrhea in women. These are two of the most pervasive STIs in the United States.
Register and access this filing in:     
  FORM 424B5
    TABLE OF CONTENTS
    ABOUT THIS PROSPECTUS SUPPLEMENT
    SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
    Selected Financial Data
    THE OFFERING
    RISK FACTORS
    USE OF PROCEEDS
    DIVIDEND POLICY
    DILUTION
    MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR HOLDERS ...
    UNDERWRITING
    LEGAL MATTERS
    EXPERTS
    WHERE YOU CAN FIND MORE INFORMATION
    RISK FACTORS
    USE OF PROCEEDS
    PLAN OF DISTRIBUTION
    DESCRIPTION OF CAPITAL STOCK
    Transfer Agent and Registrar
    DESCRIPTION OF DEBT SECURITIES
    DESCRIPTION OF WARRANTS
    DESCRIPTION OF UNITS
      INCORPORATION OF DOCUMENTS BY REFERENCE